{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:40:05Z","timestamp":1789501205675,"version":"build-2803163510"},"reference-count":100,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The prognosis of the antineutrophil cytoplasmic antibody associated vasculitides (AAV), microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA) and eosinophilic GPA (EGPA), has been fundamentally improved over the last five decades by the use of glucocorticoids and immunosuppressants, turning them from consistently fatal diseases into chronic conditions. The long-term course is now largely determined by the frequency of disease flares and by accruing damage caused by disease activity and treatment-related comorbidities. This review summarizes the evidence derived from clinical trials performed during the last 30 years and the remaining clinical unmet needs that new studies aim to address. In MPA and GPA, ongoing studies assess (i) different strategies to reduce cumulative glucocorticoid doses currently used for induction and maintenance of remission, (ii) the efficacy of new drugs and (iii) the optimal duration of immunosuppression and the use of biomarkers to individualize therapy. Prospective randomized trials also target disease-associated cardiovascular risk and infections. The first prospective controlled trials specifically designed for EGPA have recently been launched and could lead to new therapeutic options for patients diagnosed with this rare disease. This is an exciting time for researchers in the field of AAV, and for patients as collaborative efforts raise the hope of developing new therapies and more individualized approaches to the management of the diseases, maximizing efficacy while minimizing treatment toxicities.<\/jats:p>","DOI":"10.1093\/ndt\/gfw384","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T07:05:45Z","timestamp":1481180745000},"page":"i37-i47","source":"Crossref","is-referenced-by-count":7,"title":["Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn"],"prefix":"10.1093","volume":"32","author":[{"given":"Divi","family":"Cornec","sequence":"first","affiliation":[{"name":"Thoracic Disease Research Unit, Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, MN, USA"},{"name":"European University of Brittany and Brest University Hospital, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Cornec-Le Gall","sequence":"additional","affiliation":[{"name":"European University of Brittany and Brest University Hospital, Brest, France"},{"name":"Division of Nephrology, Mayo Clinic Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[{"name":"Thoracic Disease Research Unit, Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"2025102312484836900_gfw384-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","article-title":"ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients","volume":"12","author":"Cornec","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2025102312484836900_gfw384-B3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Int Med"},{"key":"2025102312484836900_gfw384-B4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of the respiratory tract (Wegener\u2019s granulomatosis)","volume":"2","author":"Walton","year":"1958","journal-title":"Br Med J"},{"key":"2025102312484836900_gfw384-B5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0002-9343(67)90144-1","article-title":"Long-term follow-up study of periarteritis nodosa","volume":"43","author":"Frohnert","year":"1967","journal-title":"Am J Med"},{"key":"2025102312484836900_gfw384-B6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-67-2-393","article-title":"The use of alkylating agents in the treatment of Wegener\u2019s granulomatosis","volume":"67","author":"Hollander","year":"1967","journal-title":"Ann Intern Med"},{"key":"2025102312484836900_gfw384-B7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener\u2019s granulomatosis: studies in eighteen patients and a review of the literature","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine"},{"key":"2025102312484836900_gfw384-B8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"2025102312484836900_gfw384-B9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"2025102312484836900_gfw384-B10","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/1529-0131(199912)42:12<2666::AID-ANR24>3.0.CO;2-E","article-title":"A staged approach to the treatment of Wegener\u2019s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance","volume":"42","author":"Langford","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"2025102312484836900_gfw384-B12","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener\u2019s granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B13","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Int Med"},{"key":"2025102312484836900_gfw384-B14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025102312484836900_gfw384-B15","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/art.21146","article-title":"Methotrexate for Wegener\u2019s granulomatosis: what is the evidence?","volume":"52","author":"Specks","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B16","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.39472","article-title":"Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A French Nationwide Study of Ninety-Two Patients","volume":"68","author":"Crickx","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025102312484836900_gfw384-B18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"key":"2025102312484836900_gfw384-B19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.06010809","article-title":"Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement\u2013a prospective, open-label pilot trial","volume":"5","author":"Silva","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312484836900_gfw384-B20","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ndt\/gfm780","article-title":"Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement","volume":"23","author":"Hu","year":"2008","journal-title":"Nephrol Dial Transpl"},{"key":"2025102312484836900_gfw384-B21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2025102312484836900_gfw384-B22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"2025102312484836900_gfw384-B23","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement","volume":"26","author":"Geetha","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025102312484836900_gfw384-B24","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025102312484836900_gfw384-B25","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025102312484836900_gfw384-B27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2025102312484836900_gfw384-B28","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025102312484836900_gfw384-B29","doi-asserted-by":"crossref","first-page":"i146","DOI":"10.1093\/ndt\/gfv051","article-title":"Plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis\u2013a 25-year perspective","volume":"30 (Suppl 1)","author":"Szpirt","year":"2015","journal-title":"Nephrol Dial Transpl"},{"key":"2025102312484836900_gfw384-B30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/ki.1991.272","article-title":"Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies","volume":"40","author":"Pusey","year":"1991","journal-title":"Kidney Int"},{"key":"2025102312484836900_gfw384-B31","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse alveolar hemorrhage secondary to ANCA-associated vasculitis: predictors of respiratory failure and clinical outcomes","volume":"68","author":"Cartin-Ceba","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025102312484836900_gfw384-B32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaut.2015.08.003","article-title":"Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: data from the French vasculitis study group","volume":"65","author":"de Luna","year":"2015","journal-title":"J Autoimmun"},{"key":"2025102312484836900_gfw384-B33","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.1780381116","article-title":"Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients","volume":"38","author":"Guillevin","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B34","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2025102312484836900_gfw384-B35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2013.131","article-title":"Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear","volume":"84","author":"Walsh","year":"2013","journal-title":"Kidney Int"},{"key":"2025102312484836900_gfw384-B36","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis","volume":"62","author":"Beck","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2025102312484836900_gfw384-B37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","article-title":"Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials","volume":"54","author":"Robson","year":"2015","journal-title":"Rheumatology"},{"key":"2025102312484836900_gfw384-B38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025102312484836900_gfw384-B39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1745-6215-14-73","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial","volume":"14","author":"Walsh","year":"2013","journal-title":"Trials"},{"key":"2025102312484836900_gfw384-B40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025102312484836900_gfw384-B41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2025102312484836900_gfw384-B42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1681\/ASN.2013101043","article-title":"With complements from ANCA mice","volume":"25","author":"Kettritz","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2025102312484836900_gfw384-B43","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2006.060301","article-title":"Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide","volume":"66","author":"Stassen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2025102312484836900_gfw384-B44","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.lpm.2013.02.067","article-title":"A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: \u2018MYCYC\u2019: on behalf of the European vasculitis study group","volume":"42","author":"Jones","year":"2013","journal-title":"Presse Med"},{"key":"2025102312484836900_gfw384-B45","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025102312484836900_gfw384-B46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2015.02.002","article-title":"Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab","volume":"45","author":"Berti","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B47","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/ard.2007.081661","article-title":"Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)","volume":"67","author":"Walsh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2025102312484836900_gfw384-B48","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/rheumatology\/ket451","article-title":"Gusperimus: immunological mechanism and clinical applications","volume":"53","author":"Perenyei","year":"2014","journal-title":"Rheumatology"},{"key":"2025102312484836900_gfw384-B49","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"key":"2025102312484836900_gfw384-B50","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"2025102312484836900_gfw384-B51","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2025102312484836900_gfw384-B52","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","article-title":"Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener\u2019s granulomatosis","volume":"46","author":"Metzler","year":"2007","journal-title":"Rheumatology"},{"key":"2025102312484836900_gfw384-B53","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"2025102312484836900_gfw384-B54","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/art.39450","article-title":"Long-term outcomes of the WEGENT trial on remission-maintenance for granulomatosis with polyangiitis or microscopic polyangiitis","volume":"68","author":"Puechal","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025102312484836900_gfw384-B55","doi-asserted-by":"crossref","first-page":"i60","DOI":"10.1093\/ndt\/gfu392","article-title":"The long-term outcomes of systemic vasculitis","volume":"30 (Suppl 1)","author":"Westman","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312484836900_gfw384-B56","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1002\/art.39317","article-title":"Incidence of malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis diagnosed between 1991 and 2013","volume":"67","author":"Rahmattulla","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025102312484836900_gfw384-B57","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/art.39104","article-title":"Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids","volume":"67","author":"Miloslavsky","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025102312484836900_gfw384-B58","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B59","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","article-title":"Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients","volume":"53","author":"Charles","year":"2014","journal-title":"Rheumatology"},{"key":"2025102312484836900_gfw384-B60","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2014.03.002","article-title":"Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener\u2019s): results of a single-center cohort study on 66 patients","volume":"50","author":"Calich","year":"2014","journal-title":"J Autoimmun"},{"key":"2025102312484836900_gfw384-B61","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology"},{"key":"2025102312484836900_gfw384-B62","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","article-title":"Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre","volume":"52","author":"Besada","year":"2013","journal-title":"Rheumatology"},{"key":"2025102312484836900_gfw384-B63","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): ten-year experience at a single center","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"2025102312484836900_gfw384-B65","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keu194","article-title":"Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis","volume":"53","author":"Besada","year":"2014","journal-title":"Rheumatology"},{"key":"2025102312484836900_gfw384-B66","doi-asserted-by":"crossref","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","author":"Venhoff","year":"2012","journal-title":"PLoS One"},{"key":"2025102312484836900_gfw384-B67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2014.11.004","article-title":"Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"2025102312484836900_gfw384-B68","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/art.39637","article-title":"Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3","volume":"68","author":"Fussner","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025102312484836900_gfw384-B69","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MD.0000000000000020","article-title":"Granulomatosis with polyangiitis (Wegener\u2019s): impact of maintenance therapy duration","volume":"93","author":"Springer","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2025102312484836900_gfw384-B70","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ndt\/gfw211","article-title":"Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial","volume":"31","author":"Sanders","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312484836900_gfw384-B71","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2215\/CJN.05610611","article-title":"Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease","volume":"7","author":"McGregor","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312484836900_gfw384-B72","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025102312484836900_gfw384-B73","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.autrev.2015.06.008","article-title":"Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides","volume":"14","author":"Dumoitier","year":"2015","journal-title":"Autoimm Rev"},{"key":"2025102312484836900_gfw384-B74","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/rheumatology\/kev293","article-title":"Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro","volume":"55","author":"Lepse","year":"2016","journal-title":"Rheumatology"},{"key":"2025102312484836900_gfw384-B75","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaut.2014.01.018","article-title":"Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome)","volume":"48\u201349","author":"Mouthon","year":"2014","journal-title":"J Autoimm"},{"key":"2025102312484836900_gfw384-B76","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.autrev.2014.12.004","article-title":"Churg-Strauss syndrome","volume":"14","author":"Greco","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2025102312484836900_gfw384-B77","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B78","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.autrev.2015.10.006","article-title":"Dividing the Janus vasculitis? Pathophysiology of eosinophilic granulomatosis with polyangitis","volume":"15","author":"Chaigne","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2025102312484836900_gfw384-B79","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9343(03)00359-0","article-title":"Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists","volume":"115","author":"Keogh","year":"2003","journal-title":"Am J Med"},{"key":"2025102312484836900_gfw384-B80","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/art.21250","article-title":"Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome","volume":"52","author":"Sinico","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B81","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/art.23198","article-title":"Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients","volume":"58","author":"Ribi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B82","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.22679","article-title":"Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients","volume":"57","author":"Cohen","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2025102312484836900_gfw384-B83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","article-title":"Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients","volume":"75","author":"Guillevin","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"2025102312484836900_gfw384-B84","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French vasculitis study group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"2025102312484836900_gfw384-B85","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","article-title":"Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials","volume":"43","author":"Samson","year":"2013","journal-title":"J Autoimmun"},{"key":"2025102312484836900_gfw384-B86","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.autrev.2014.08.002","article-title":"Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors","volume":"13","author":"Samson","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2025102312484836900_gfw384-B87","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/art.39663","article-title":"Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data from 17 patients","volume":"68","author":"Jachiet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025102312484836900_gfw384-B88","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/ndt\/gfq852","article-title":"Rituximab for the treatment of Churg-Strauss syndrome with renal involvement","volume":"26","author":"Cartin-Ceba","year":"2011","journal-title":"Nephrol Dial Transpl"},{"key":"2025102312484836900_gfw384-B89","doi-asserted-by":"crossref","first-page":"R133","DOI":"10.1186\/ar4313","article-title":"Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)","volume":"15","author":"Thiel","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2025102312484836900_gfw384-B90","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025102312484836900_gfw384-B91","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"2025102312484836900_gfw384-B92","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2025102312484836900_gfw384-B93","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Ann Intern Med"},{"key":"2025102312484836900_gfw384-B94","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/JAA.S40244","article-title":"Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases","volume":"8","author":"Menzella","year":"2015","journal-title":"J Asth Aller"},{"key":"2025102312484836900_gfw384-B95","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"2025102312484836900_gfw384-B96","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1136\/annrheumdis-2015-207601","article-title":"Genetic variants in ANCA-associated vasculitis: a meta-analysis","volume":"75","author":"Rahmattulla","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025102312484836900_gfw384-B97","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","article-title":"Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"30 (Suppl 1)","author":"Watts","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312484836900_gfw384-B98","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/art.39786","article-title":"Myeloperoxidase-ANCA associated Granulomatosis with polyangiitis is a clinically distinct subset within ANCA-associated vasculitis","volume":"68","author":"Schirmer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025102312484836900_gfw384-B99","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/art.39812","article-title":"Myeloperoxidase-ANCA-positive and ANCA-negative patients with granulomatosis with polyangiitis: distinct patient subsets","volume":"68","author":"Miloslavsky","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025102312484836900_gfw384-B100","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/art.39860","article-title":"Classifying ANCA-associated vasculitides according to ANCA Type or phenotypic diagnosis: salt or pepper?","volume":"68","author":"Pagnoux","year":"2016","journal-title":"Arthritis Rheumatol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/suppl_1\/i37\/23000586\/gfw384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/suppl_1\/i37\/23000586\/gfw384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:49:30Z","timestamp":1761238170000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/32\/suppl_1\/i37\/2900579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":100,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2017,1,20]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw384","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1]]},"published":{"date-parts":[[2017,1,1]]}}}